Performance of DNLI Denali Therapeutics | -35.1% in 12m
Compare DNLI with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Denali Therapeutics with its related Sector/Index XBI
Performance Duell DNLI vs XBI
| TimeFrame | DNLI | XBI |
|---|---|---|
| 1 Day | 1.33% | -1.52% |
| 1 Week | 6.27% | 1.45% |
| 1 Month | 28.2% | 10.08% |
| 3 Months | 24.0% | -1.30% |
| 6 Months | 6.88% | 24.09% |
| 12 Months | -35.1% | 6.83% |
| YTD | -4.11% | 1.05% |
| Rel. Perf. 1m | 1.03 | |
| Rel. Perf. 3m | -0.39 | |
| Rel. Perf. 6m | -1.58 | |
| Rel. Perf. 12m | -4.70 |
Is Denali Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Denali Therapeutics (NASDAQ:DNLI) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -60.35 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of May 2024 is 17.39. This means that DNLI is currently overvalued and has a potential downside of -15.21% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of May 2024 is 17.39. This means that DNLI is currently overvalued and has a potential downside of -15.21% (Sold with Premium).
Is DNLI a buy, sell or hold?
- Strong Buy: 11
- Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
Values above 0%: DNLI is performing better - Values below 0%: DNLI is underperforming
Compare DNLI with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 4.63% | 21.26% | -10.51% | -63.36% |
| US NASDAQ 100 | QQQ | 4.31% | 19.24% | -9.18% | -70.20% |
| US Dow Jones Industrial 30 | DIA | 4.88% | 22.73% | -7.90% | -56.96% |
| German DAX 40 | DBXD | 6.51% | 23.04% | -10.28% | -49.43% |
| UK FTSE 100 | ISFU | 4.73% | 18.64% | -9.36% | -49.70% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 5.12% | 23.46% | 4.76% | -27.77% |
| Hongkong Hang Seng | HSI | 4.12% | 5.33% | 3.19% | -29.64% |
| Japan Nikkei 225 | EXX7 | 5.21% | 27.31% | -4.90% | -45.78% |
| India NIFTY 50 | INDA | 3.85% | 24.99% | -10.70% | -64.87% |
| Brasil Bovespa | EWZ | 6.36% | 24.90% | 10.64% | -47.76% |
DNLI Denali Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 5.08% | 24.24% | -10.30% | -70.83% |
| Consumer Discretionary | XLY | 5.80% | 22.92% | 0.09% | -53.88% |
| Consumer Staples | XLP | 5.22% | 23.13% | -7.44% | -41.08% |
| Energy | XLE | 4.80% | 28.20% | -7.08% | -58.41% |
| Financial | XLF | 4.28% | 22.96% | -15.05% | -67.71% |
| Health Care | XLV | 4.28% | 22.89% | -7.43% | -48.30% |
| Industrial | XLI | 6.13% | 24.16% | -12.45% | -62.76% |
| Materials | XLB | 5.87% | 24.60% | -8.94% | -54.65% |
| Real Estate | XLRE | 4.03% | 20.16% | -1.92% | -45.91% |
| Technology | XLK | 3.70% | 18.17% | -7.78% | -70.65% |
| Utilities | XLU | 4.77% | 17.63% | -11.68% | -48.24% |
| Aerospace & Defense | XAR | 5.20% | 19.83% | -7.37% | -59.48% |
| Biotech | XBI | 4.82% | 18.11% | -17.21% | -41.88% |
| Homebuilder | XHB | 5.69% | 21.19% | -23.38% | -85.90% |
| Retail | XRT | 6.75% | 21.50% | -13.22% | -64.55% |
Does Denali Therapeutics outperform its market, is DNLI a Sector Leader?
No, over the last 12 months Denali Therapeutics (DNLI) made -35.05%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months DNLI made 24.00%, while XBI made -1.30%.
No, over the last 12 months Denali Therapeutics (DNLI) made -35.05%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months DNLI made 24.00%, while XBI made -1.30%.
| Period | DNLI | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 28.19% | 10.08% | 6.93% |
| 3 Months | 24.00% | -1.30% | 6.91% |
| 12 Months | -35.05% | 6.83% | 28.31% |